MonarchE: A randomized, open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, HR+, HER2-breast cancer

被引：0
|
作者：
Rastogi, Priya
Toi, Masakazu
Harbeck, Nadia
Bourayou, Nawel
Frenzel, Martin
Johnston, Stephen
机构：
[1] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[2] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[3] Univ Munich LMU, Breast Ctr, Munich, Germany
[4] Eli Lilly & Co, Paris, France
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Royal Marsden NHS Fdn Trust, London, England
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-05-05
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2-breast cancer
    Edwards, Teresa
    Norcross, Lindsey
    Fine, Jennifer
    Martin, Susan
    Coulouvrat, Catherine
    Spears, Patricia
    Herold, Christina Isabella
    Ferrari, Giorgio
    Onwudiwe, Nneka
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study
    Rugo, H. S.
    O'Shaughnessy, J.
    Boyle, F.
    Toi, M.
    Broom, R.
    Blancas, I
    Gumus, M.
    Yamashita, T.
    Im, Y-H
    Rastogi, P.
    Zagouri, F.
    Song, C.
    Campone, M.
    San Antonio, B.
    Shahir, A.
    Hulstijn, M.
    Brown, J.
    Zimmermann, A.
    Wei, R.
    Johnston, S. R. D.
    Reinisch, M.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 616 - 627
  • [33] Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy
    Davie, Alison
    Traore, Sory
    Giovannitti, Massimo
    Pompilio, Giuseppe
    Lambton, Mark
    Cakar, Esra
    Chatterjee, Anuja
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2023, 10 : 62 - 69
  • [34] A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)
    Loibl, Sibylle
    Park, Yeon
    Tolaney, Sara
    Gioni, Ioanna
    Johnston, Simon
    Klinowska, Teresa
    Mayer, Ingrid A.
    Nunes, Raquel
    Pistilli, Barbara
    Stuart, Mary
    Quintana, Angela
    Walding, Andrew
    Gnant, Michael
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study
    Zhang, Qingyuan
    Shen, Kunwei
    Song, Chuan-gui
    Ouyang, Quchang
    Liu, Zhenzhen
    Liu, Qiang
    Feng, Jifeng
    Chiu, Joanne W. Y.
    Tang, Jinhai
    Jiang, Zefei
    Tseng, Ling-Ming
    Wang, Xiaojia
    Yang, Liu
    Qian, Chenxi
    Shao, Zhimin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [36] Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2- early breast cancer (vol 15, 17588359231178125, 2023)
    Slamon, D. J.
    Fasching, P. A.
    Hurvitz, S.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [37] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
    Fleming, G. F.
    Pagani, O.
    Regan, M. M.
    Walley, B. A.
    Francis, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (06) : 658 - 658
  • [38] Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study
    Harbeck, N.
    Rastogi, P.
    Martin, M.
    Tolaney, S. M.
    Shao, Z. M.
    Fasching, P. A.
    Huang, C. S.
    Jaliffe, G. G.
    Tryakin, A.
    Goetz, M. P.
    Rugo, H. S.
    Senkus, E.
    Testa, L.
    Andersson, M.
    Tamura, K.
    Del Mastro, L.
    Steger, G. G.
    Kreipe, H.
    Hegg, R.
    Sohn, J.
    Guarneri, V
    Cortes, J.
    Hamilton, E.
    Andre, V
    Wei, R.
    Barriga, S.
    Sherwood, S.
    Forrester, T.
    Munoz, M.
    Shahir, A.
    San Antonio, B.
    Nabinger, S. C.
    Toi, M.
    Johnston, S. R. D.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1571 - 1581
  • [39] Primary outcome analysis of invasive disease-free survival for monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
    O'Shaughnessy, Joyce A.
    Johnston, Stephen
    Harbeck, Nadia
    Toi, Masakazu
    Im, Young-Hyuck
    Reinisch, Mattea
    Shao, Zhimin
    Lehtinen, Pirkko Liisa Kellokumpu
    Huang, Chiun-Sheng
    Tryakin, Alexey
    Goetz, Matthew
    Rugo, Hope S.
    Senkus, Elzbieta
    Testa, Laura
    Andersson, Michael
    Tamura, Kenji
    Steger, Guenther G.
    Del Mastro, Lucia
    Cox, Joanne
    Forrester, Tammy
    Sherwood, Sarah
    Li, Xuelin
    Wei, Ran
    Martin, Miguel
    Rastogi, Priya
    CANCER RESEARCH, 2021, 81 (04)
  • [40] Abemaciclib combined with adjuvant endocrine therapy in patients with high risk early breast cancer who received neoadjuvant chemotherapy (NAC)
    Park-Simon, Tjoung-Won
    Martin, Miguel
    Hegg, Roberto
    Kim, Sung-Bae
    Schenker, Michael
    Grecea, Daniela
    Garcia-Saenz, Jose Angel
    Papazisis, Konstantinos
    Ouyang, Quchang
    Lacko, Aleksandra
    Oksuzoglu, Berna
    Reeves, James
    Okera, Meena
    Testa, Laura
    Shimizu, Chikako
    Wei, Ran
    Forrester, Tammy
    Munoz, Maria
    Zimmermann, Annamaria
    Headley, Desiree
    Johnston, Stephen
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 28 - 29
12345